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Summary: The accumulation of a glucosphingolipid (GSL) in individuals
lacking an adequate level of hydrolase activity could be minimized by
chemotherapeutic measures that slow the formation of the GSL and stimulate
the defective hydrolase. By achieving a balance in the rates of formation and
breakdown, one should be able to alleviate the symptoms of excess storage
and achieve a satisfactory accommodation. While several drugs seem to be
speci¢cally suitable for this purpose, only one of these has been approved for
human use. However, less effective drugs and over-the-counter substances
are available for human use and may prove satisfactory for a few years until
better ones are made available. The proposed materials and the evidence behind
the recommendations are presented in this paper.
Disclaimer: The ideas expressed here are strictly my own and the Journal of
Inherited Metabolic Disease certainly does not endorse the proposals. I am
not a medical doctor, merely a biochemist with 48 years of research experience
with sphingolipids, and must point out to the medical and lay (patient) reader
that none of the approaches have been tried for the purpose of sphingolipidosis
therapy. The approaches are based on published work in peer-edited journals,
referenced below so that the reader can check the accuracy of the citations
and the quality of the research work. Many önot allöof the reported obser-
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vations were obtained with cultured cancer cells, which are quite different from
live individuals, despite the claims of some animal protectionists. The drugs
and `health supplements' named here are in common use and deserve serious
consideration. Probably the best way to proceed is to start with one approach,
then add a second, then add a third. As with all pharmaceutical products, com-
binations of the suggested materials might interact in unexpected ways. An
open-minded, caring doctor must approve the suggestions and intelligently
monitor the results of their use. Each patient must decide for himself or herself
whether the unknown risks inherent in any form of therapy are warranted by
the intensity of the af£iction.
The dosages used with the currently approved drugs were all designed to achieve a
speci¢c therapeutic effect, usually the death of cancer cells. (There is an important
clue in this relationship: cancer of the B cells is especially common in Gaucher
patients and elevated levels of glucosylceramide (GlcCer) produce cell proliferation
(Radin 1999).) I doubt that anyone analysed a cancer patient for his GlcCer content
during chemotherapy, so one cannot guess whether the drug would indeed help a
glucosphingolipidosis patient. Only the standard empirical methodögradual
increases in dosageöcan tell us the optimum dose for metabolite balance therapy.
Perhaps a research-minded researcher will run appropriate trials after reading this
article. This is important, because the treatments will have to be continued until
more speci¢c and reactive drugs are approved for human useöperhaps until the
end of 2002. A patient following my suggestions should not expect rapid recovery
to a normal state because of the abnormally low activities of the defective enzyme
and the large `reservoir' of accumulated GSL. Once the stored GSL has been brought
to the normal level, therapy can be stopped for a while, or reduced in intensity, since
the GSL accumulation process is usually rather slow.
My suggestions should also be considered with the idea in mind of simultaneously
using commercially available enzymes, such as Glucerase or Ceredase, but at a lower
dosage. This would greatly reduce the cost of therapy. Similarly, the suggested treat-
ments could be used to reduce the dosage of a GlcCer synthase inhibitor once it has
been approved for use.
THE RATIONALE
The glucosphingolipid disorders (Gaucher, Tay^Sachs, Sandhoff, Fabry, GM1-
gangliosidosis, fucosidosis) are genetic disorders due to abnormally low activities
of the hydrolases (or their natural stimulators) that break down glucosphingolipids
(GSLs) to smaller molecules. As with most chemicals in the body, the GSLs are
formed by cells; then, after they have `done their duty' for a certain length of time,
they are broken down into smaller molecules that can be recycled to make new GSLs
or broken down further for other uses. In patients with these genetic disorders, the
ability to hydrolyse a speci¢c GSL is low and the unremitting £ow of new GSL
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molecules produces a pile-up of accumulating GSLs that cannot carry out their func-
tion and simply cause trouble.
In Gaucher disease, there is accumulation of the simplest GSL, GlcCer. The
defective enzyme is GlcCer glucosidase, which normally removes glucose from
GlcCer, leaving behind a basic sphingolipid, ceramide. The other GSLs in this dis-
ease group are all formed from GlcCer by enzymes that attach additional sugars
and other moieties. In sulphatidosis, several GSLs accumulate, most of them derived
from GlcCer, and the techniques described in this paper might alleviate some of the
symptoms in this disorder. The same applies to Fabry patients.
At present it is possible to periodically inject Gaucher patients with GlcCer
glucosidase (modi¢ed to improve cellular uptake) and thus overcome the lack of
adequate enzyme activity. The cost of this enzyme is enormous. Fabry patients
may soon be able to supplement their defective a-galactosidase with injections of
normal enzyme, also at great ¢nancial cost. Some day it may be possible to get injec-
tions of the normal gene that will once-and-for-all displace the defective gene and
produce a long-lived cure. Since 1981 I have been publishing articles proposing
a simpler treatment for the sphingolipid disorders: slow the rate of synthesizing
the GSL that has been accumulating, so that the rate of formation equals the
patient's rate of GSL breakdown (Radin 1996). Simultaneously, I suggest in this
paper, one should also stimulate the rate of GSL breakdown. I suggest calling this
approach metabolite balance therapy. Several methods could be used, together
or separately, to achieve the balance: (a) the enzyme that produces the undesired
metabolite could be slowed by an inhibitor; or (b) the enzyme's activator (if known)
could be prevented from binding to the enzyme; or (c) the concentration of substrate
used by the enzyme could be reduced by slowing its formation or diverting it to a
di¡erent metabolic pathway; or (d) the speed of the metabolite's destruction could
be increased by stimulating a suitable enzyme. Other methods could also be useful.
Metabolite balance therapy need not be restricted to the GSL disorders.
This idea is based on the fact that many sphingolipidosis patients contain some
residual hydrolytic activity, sometimes as much as 10^30% of the normal amount
of activity. The rate of formation need not be slowed much, since the normal activity
of the hydrolase is somewhat greater than the normal activity of the synthesizing
enzyme. In other words, the normal body has excess degradative activity compared
to the amount of synthase and can accommodate to appreciable loss of the
degradative enzyme. My proposal is thus based on simple arithmetic and it assumes
that the slowed rate of synthesis and accelerated rate of hydrolysis will not cause
damage to the patient and that the accumulated lipid is accessible to the defective
hydrolase. Ideally, normalizing the tissue concentration of the a¡ected GSL will
not result in accumulation of precursors or decreases in the GSLs derived from
the a¡ected GSL. It is possible that more than one enzyme will have to be controlled.
Other researchers have called this approach `substrate deprivation therapy' (Abe
et al 2000b; Jeyakumar et al 1999). This term would be appropriate if, indeed, a
substrate for the enzyme to be slowed is actually reduced in concentration, as in
approach (c). In the case of Gaucher disease, the synthase's substrates are ceramide
and UDP-glucose, notGlcCer. Reducing the concentration of either substrate would
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slow the synthesis of GlcCer. If one simply inhibits the enzyme, the term is
inappropriate. For patients su¡ering disorders of the more complex GSLs that
accumulate in the (non-Gaucher) glucosphingolipid storage diseases, lowering
the concentration of GlcCer might slow the enzymes involved in the synthesis of
the undesired metabolite and `substrate deprivation' would be an appropriate term.
The essence of the balance approach, however, is in equalizing the rates of anabolism
and catabolism.
PROOF OF CONCEPT
Several recent reports support the value of metabolite balance therapy. One study
was done with mice suffering from a galactosphingolipidosis, globoid cell
leukodystrophy (LeVine et al 2000). These `twitcher' mice have an inadequate
activity of the b-galactosidase acting on galactosylceramide. Slowing the synthesis
of the galactolipid by slowing the synthesis of one of its precursors, `ketosphingosine'
(2-amino-3-keto-octadecanol-1), with L-cycloserine produced a partial bene¢cial
effect on the mice. Since cycloserine blocks formation of all the sphingolipids, this
technique cannot produce a fully satisfactory effect, but it might have merit when
combined with a more speci¢c method of achieving metabolite balance. It was found
to augment the depleting action of an inhibitor of GlcCer synthesis, PDMP (see
below), producing a 50% loss of GlcCer and 33% loss of lactosylceramide in mouse
kidneys after 4 days (Shukla et al 1991). Note that the cycloserine that is used
as an antibiotic is the D-isomer.
A similar test utilized oral administration of NB-DNJ (N-butyldeoxynojirimycin)
to slow GlcCer synthase in human subjects su¡ering with Gaucher disease (Cox et al
2000). This inhibitor is not as potent or as speci¢c as one would desire, since it also
inhibits a glycoprotein a-glucosidase, but it was tolerated over a year, diarrhoea
being the major side-e¡ect (Cox et al 2000; Platt and Butters 1998). Peripheral
neuropathy appeared in two of the 28 subjects. A sign of a positive e¡ect was a
decrease of 39% within a year in ganglioside GM1, a product of GlcCer, measured
in white cells. Other signs of e¡ectiveness were decreases of 7% and 15% in liver
and spleen sizes, respectively. Haemoglobin and platelet concentrations also
improved. A chemically similar, more speci¢c inhibitor has been found to show fewer
side-e¡ects in animals but has not yet been approved for human use (Andersson et al
2000).
Another recent test of metabolite balance therapy was described for knockout
mice lacking the a-galactosidase needed for globotriaosylceramide (Gb3) hydrolysis
(Abe et al 2000b). This is a form of Fabry disease that is extreme, in that the enzyme
concentration is zero. Thus one can only show that the rate of GSL accumulation is
lower than in untreated mice. Here a new variant of D-threo-PDMP was used
to block GlcGer synthesis. PDMP is D-threo-1-phenyl-2-decanoylamino-3-
morpholino-1-propanol; PPPP (`P4') is 1-phenyl-2-palmitoylamino-3-pyrrolidino-
1-propanol; and the variant was 30,40-ethylenedioxy-P4 (Lee et al 1999). All three
drugs strongly inhibit the synthesis of GlcCer. PDMP has also been shown to slow
lactosylceramide and Gb3 synthesis (Chatterjee et al 1996). Eight-week-old mice
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that had already accumulated a signi¢cant amount of Gb3 were given intra-
peritoneal injections twice a day with the `P-drug' at 10 mg/kg for 8 weeks. The
concentrations of Gb3 found in kidney, liver and heart were roughly one-half that
seen in the control mice. No signs of toxicity were seen when the treated mice were
compared with regard to weight of body and six di¡erent organs, blood urea nitrogen
and other markers. Electron microscopy showed the usual Fabry lipid inclusions in
the control mice, but these were absent from the treated mice. Thus this test
demonstrates the safety and e¡ectiveness of the approach, even in an extreme form
of a sphingolipidosis.
The same P-drug was also shown to normalize cultured Fabry cells that had been
transformed with the Epstein^Barr virus (Abe et al 2000a). The method used to
monitor the decrease in Gb3, measurement of the amount of £uorescent verotoxin
binding to the cells, could be used to monitor treated patients.
THE TOXICITY QUESTION
In a study with normal mice, PDMP was found to quickly lower the concentration of
GlcCer in the kidneys without producing any noticeable harm (Shukla et al 1991).
The decrease was one-third of the normal concentration after only 5 h. Young mice
treated with high doses of PDMP for 12 days gained less weight than control mice
and, 40 h later, were found to have relatively normal organ weights except for
the kidneys, which were 11% smaller (Inokuchi et al 1987). Blood cell counts were
normal. Other mice that were injected with cancer cells and then treated with PDMP
for 10 days survived the cancer exposure and lived as active a life as the controls for
months.
A study with normal mice and NB-DNJ over a 118-day period also yielded large
decreases in several GSLs in several organs (Platt et al 1997). Mice treated for 8
weeks with NB-DNJ looked and grew normally, but the spleen and thymus devel-
oped cell loss. Nevertheless, their immune system seemed to be normal. These studies
showed no marked toxicity due to the inhibitors. A lower dose could probably give
fewer side-e¡ects yet be e¡ective for simply slowing GSL synthesis. As noted above,
Gaucher patients improved on treatment with NB-DNJ (300 mg/day) for over a
year despite problems with diarrhoea. Mice treated with P-drugs did not exhibit
diarrhoea, possibly because of higher speci¢city of action.
The GSLs, which take part in many cell functions and which cause so much
anguish when they accumulate, do not seem to be very essential for life, at least
in the laboratory. Yeast cells that are unable to make sphingolipids because of a
genetic error grow almost as fast as normal yeast. Fish raised from the embryonic
stage in water containing PDMP, which greatly depleted them of their GSLs, grew
almost as fast as ¢sh in plain water during the hatching phase (Fenderson et al 1992).
After they were transferred to plain water, they could not be distinguished from the
control ¢sh. Cells growing in the presence of a P-drug lose almost all their GSLs
but survive at least a week, provided the concentration of inhibitor is not too high.
Perhaps most of the GSL in normal people is like stored fat, used as a backup
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for stresses or emergencies. It is also possible that a chronic de¢ciency of GSLs has
important bene¢cial value (Radin 1999).
The rest of this article describes the available materials that can be expected to
deplete patients of their accumulated GSLs.
SLOWING GlcCer SYNTHESIS
From Myles Cabot's laboratory we learn that tamoxifen, verapamil, and
doxorubicin slow GlcCer synthesis from UDP-glucose and ceramide (Cabot et al
1996; Lavie et al 1997). Doxorubicin (Adriamycin) tends to be somewhat toxic
and it normally has to be injected slowly into patients over a long period, so it does
not appear suitable for chronic use. Nevertheless, it might be useful in crisis
situations or as an initial treatment. Tamoxifen can be used chronically; it ¢nds
much use in breast cancer therapy and looks very promising for the prevention
of breast cancer metastasis and even for preventing breast cancer in the ¢rst place.
The abortion-inducing drug, RU486 (mifepristone), inhibits conversion of
ceramide to GlcCer (Lucci et al 1999) and has also shown promise in cancer therapy
(Koide 1998). It is especially e¡ective in vivo when combined with a second inhibitor
of GlcCer synthase, tamoxifen (El Etreby and Liang 1998). This drug has been much
studied in normal and cancer-bearing women and might be very valuable in
glucosphingolipidosis therapy. Relatively long-term tests indicate that it produces
slight to moderate adverse e¡ect, attributed to its inhibition of glucocorticoids
(Koide 1998). While anti-abortionists have fought against its use, it is available
in several countries and will surely soon be available in the United States.
A vitamin A derivative showing promise in cancer therapy, all-trans-retinoic acid,
was found to slow the formation of GlcCer (Madison et al 1998). A related drug
made from retinoic acid, fenretinide, may be a more e¡ective inhibitor (Maurer
1999) and has been tried in patients.
There are probably other antineoplastic drugs that also act against GlcCer syn-
thesis but simply have not been tested for that capability. A test of this hypothesis
might prove very useful.
Several reports have shown that concentrated glucose in growth media promotes
cell growth (El-Khatib et al 1996). The level of UDP-glucose is increased by a high
glucose level in vivo, and this nucleotide has been shown to be rate-limiting in
the synthesis of GlcCer in kidney cells (Zador et al 1993). Diabetic rats developed
enlarged kidneys owing to the high blood glucose levels, and lowering GlcCer levels
with PDMP shrank the kidneys back to normal despite the high glucose availability.
Since GlcCer promotes cell growth (Radin 1999), the growth-promoting property of
glucose seems to be expressed by more rapid GlcCer synthesis. Conversely, one ¢nds
slow growth in low-glucose media; thus one would expect to get slower GSL syn-
thesis if the glucose level in tissues were below normal. Because the brain needs
so much glucose, we cannot let our blood glucose concentration decrease very
far (perhaps 70 mg/100 ml is safe), but it is certainly possible to reduce one's sugar
intake appreciably, given su¤cient incentive. Some diabetics are greatly helped
by intake of a drug (such as acarbose or miglitol) that slows the digestion of starches,
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so that blood glucose levels do not rise as much as usual after a meal. Perhaps such
drugs would help to slow postprandial elevation of GSL synthesis in nondiabetic
sphingolipidosis patients.
Glucose is formed in the body from dietary carbohydrates and amino acids, so a
reduction in total food intake can be expected to slow the synthesis of GSLs. Studies
with various animal species have clearly demonstrated that a calorie-restricted diet
leads to considerable prolongation of life and postponement of degenerative
disorders. Part of the explanation may devolve on the reduction in plasma
insulin-like growth factor-1 seen in such animals (Sonntag et al 1999). This factor
acts to elevate plasma glucose levels, so a reduction in IGF-1 can be expected to
slow GlcCer synthesis.
Another way to slow the conversion of glucose to GlcCer is to eat sugars that
compete against glucose for the enzymes involved in GlcCer synthesis. Glucosamine,
a naturally occurring sugar, is readily available as an over-the-counter tablet for
treatment of joint pain. Its ability to extend the survival of mice bearing Ehrlich
ascites carcinoma (Gonzalez and Amos 1977) suggests that it does slow GlcCer syn-
thesis in vivo (Radin 1999). This observation is consistent with the similar e¡ect of
PDMP (Inokuchi et al 1987). Tests with rats, using quite high doses of glucosamine,
have yielded undesirable changes in the way the body uses glucose and insulin, but
there is probably no harm in somewhat lower dosages, as recommended on the bottle
labels. Human studies have used over 1.5 g/day, apparently with minor e¡ects, but
long-term e¡ects have not been studied.
Glucocorticoid-like drugs used widely for various purposes should be avoided, if
possible, since they stimulate the synthesis of ceramide and GSLs (Cifone et al 1999;
Levi et al 1995). Dexamethasone and prednisone are in this category.
Chlorpromazine, a psychoactive drug having quieting e¡ects, was found to lower
GlcCer levels in mice considerably (Hospattankar et al 1982). The mechanism of
the e¡ect was not studied. Obviously it should be used at a low dosage.
SLOWING GSL SYNTHESIS BY LOWERING THE AVAILABILITY OF
CERAMIDE
Since the GSLs are formed from ceramide by adding sugar molecules, lowering the
availability of ceramide should slow their synthesis. Broken cell preparations used
for assaying GlcCer synthase show increased synthesis if ceramide is added to
the incubation tube, suggesting that the enzyme is normally unsaturated with regard
to ceramide availability. Some of the ceramide is derived from a phospho-
sphingolipid, sphingomyelin, by several hydrolases. Thus one should minimize
the rate of sphingomyelin breakdown. One factor that speeds the enzymatic break-
down is arachidonic acid (Surette et al 1999), a polyunsaturated fatty acid found
in vegetable oils and animal fats, which should be avoided. Olive oil and canola
oil have a relatively low content of arachidonic acid and are therefore to be preferred.
The risk in eating corn oil is illustrated by the observation that injection of the oil
intraperitoneally into mice produced an elevation in tissue GlcCer (Abe et al 2000b).
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Commercially prepared foods lacking fat are increasingly becoming available but
some of them include a high sugar content.
Eating fat is undesirable in another way, since part of dietary fat (and
carbohydrates) is converted in the body to palmitic acid, the precursor of
sphingosine. The palmitate ends up in both the amine and fatty acid moieties of
ceramide. Adding palmitic acid to cultured heart muscle cells produced ceramide
accumulation (Hickson-Bick et al 2000).
Another way to slow the formation of ceramide from sphingomyelin is by taking
steps to increase the concentration of glutathione (GSH) in the body. GSH normally
slows the hydrolysis of sphingomyelin (Liu and Hannun 1997; Liu et al 1998) and the
body adjusts its concentration as needed. It is destroyed by oxygen radicals, which
are formed by normal processes involving reactions between body constituents
and oxygen, as well as by radiation from natural radioactive elements in one's body.
These are the free radicals that produce cell damage and speed the ageing processes.
Food antioxidants, such as vitamin E, act to slow ceramide formation from
sphingomyelin by protecting GSH from destruction by oxygen, and thus slow
GlcCer formation. This suggests that it would be helpful to supplement one's diet
with antioxidants. GSH is available from nutrition stores. Other dietary components
have been recommended for this purpose: tofu, broccoli, cauli£ower, and Brussels
sprouts. There is a very large amount of literature on GSH and on antioxidant foods,
so it pays to study it in order to match one's food preferences and my dietary
recommendation.
GSH is normally in equilibrium with its oxidized form, GSSG, and eating thiols
will push the equilibrium in the direction of more GSH. N-Acetylcysteine seems
to be a suitable thiol.
Carnitine, another important body component sold as a nutritional supplement,
has been shown to lower cellular levels of ceramide (Andrieu-Abadie et al 1999).
It is an important component of the body's fat-burning apparatus and it ought
to be helpful, especially since it aids in the oxidative destruction of palmitic acid,
the precursor of the sphingolipids.
The use of marijuana ought to be avoided as its primary component, D9-
tetrahydrocannabinol, speeds the formation of ceramide from sphingomyelin
(Galve-Roperh et al 2000). Similarly, the use of dietary arginine supplementation
(to aid blood £ow) should be avoided, since arginine acts to stimulate nitric oxide
production, which in turn stimulates destruction of GSH and conversion of
sphingomyelin to ceramide (Ma et al 1999).
As mentioned earlier, L-cycloserine slows the synthesis of ceramide in vivo. Many
researchers have used fumonisin B1 in vitro to slow ceramide synthesis (via acylation
of sphingosine), but it tends to produce cancer, probably because it diverts
sphingosine into toxic metabolic products.
SPEEDING THE BREAKDOWN OF GlcCer
This can be done by injecting phosphatidylserine periodically, since it stimulates
activity of b-glucosidase, the enzyme that removes the glucose portion of GlcCer.
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The effect was shown in mice containing a high content of GlcCer (`Gaucher mice')
(Datta and Radin 1988). This lipid also stimulates neutral/alkaline ceramidase
(El Bawab et al 1999), so it would exert a second bene¢cial effect by lowering
the availability of ceramide (see above). It was also found to stimulate the hydrolysis
of lactosylceramide and ganglioside GM1, even in cells from patients with Krabbe
disease and GM1 gangliosidosis (Kobayashi et al 1985).
The phospholipid is available from `nutrition' stores, which tout it as a memory
enhancer for elderly people, to be taken orally. It seems unlikely that it would survive
passage intact through the digestive system, but perhaps a patient would absorb a
useful portion of the material. In view of the high price of this lipid to scientists,
I would want reliable assurance as to the purity of the preparation. No doubt better
stimulators of the sphingolipid hydrolases could be synthesized.
A complication in the use of phosphatidylserine is that it stimulates neutral
sphingomyelinase to produce ceramide, which might neutralize the e¡ort to lower
tissue ceramide.
HORMONAL CONTROL OVER GlcCer SYNTHESIS
Mouse kidney was found to be sensitive to androgen and oestrogen levels (Shukla et
al 1992). Young mice injected with testosterone showed an elevated level of GlcCer
synthase activity, more rapid synthesis of GSLs, and faster growth. Moreover
the activity of GlcCer glucosidase was decreased, an effect that joins in with the
¢rst effect to enhance GSL synthesis. 17b-Oestradiol exerted opposite effects on
GlcCer synthase and hydrolase, slowing growth or shrinking the kidneys. It seems
likely that other hormone-sensitive tissues would respond similarly. The prostate
gland is certainly one of those. Thus glucosphingolipidoses in those sites should
respond to anti-androgen, pro-oestrogen therapy by lowering GlcCer and other
GSL production. Anti-androgen drugs such as Lupron (long-lasting injectable)
and casodex should be useful. These drugs are used for long periods in men with
prostate cancer, and should be useful at lower doses without signi¢cant sexual
impairment in men. Oestrogen-like drugs, also at low doses, should help. It is
interesting that tamoxifen has oestrogenic activity and also inhibits GlcCer
synthesis, as mentioned above. This makes its use more attractive.
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